Compare MAGN & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAGN | MRVI |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.3M | 472.8M |
| IPO Year | N/A | 2020 |
| Metric | MAGN | MRVI |
|---|---|---|
| Price | $12.93 | $3.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $19.00 | $4.57 |
| AVG Volume (30 Days) | 442.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $4.09 | N/A |
| Revenue Next Year | $2.34 | $10.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.82 | $1.67 |
| 52 Week High | $20.89 | $4.11 |
| Indicator | MAGN | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 37.67 | 61.55 |
| Support Level | $12.56 | $3.25 |
| Resistance Level | $15.14 | $3.65 |
| Average True Range (ATR) | 0.56 | 0.15 |
| MACD | -0.12 | 0.07 |
| Stochastic Oscillator | 9.24 | 72.58 |
Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.